GUB014295
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
AbbVie · Phase 1 · Completed · Enrollment 76
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| GUB014295 | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- GUB014295: endpoint not reported